Circadian swallows Vegenics
Tuesday, 15 July, 2008
Circadian Technologies [ASX: CSR] is to acquire 100 per cent ownership of Vegenics as part of its strategy to transform Circadian from a biotech incubator to a full-scale drug development company.
Under the agreement, Circadian is to purchase the 33 per cent share owned by Vegenics co-founders the Ludwig Institute for Cancer Research and Licentia Limited.
Circadian will assume complete control of the rights to and development of Vegenics' VEGF technology.
In return, Circadian will give the Ludwig Institute and Licentia shares totalling 11 per cent ownership of the company, with more shares on offer once certain product development milestones are met.
Defective sperm doubles pre-eclampsia risk in IVF patients
A high proportion of the father's spermatozoa possessing DNA strand breaks is associated with...
Free meningococcal B vaccines coming to the NT
The Northern Territory Government has confirmed the rollout of a free meningococcal B vaccine...
Mouth bacteria linked to increased head and neck cancer risk
More than a dozen bacterial species that live in people's mouths have been linked to a...
